Business
Attending G8 Global CEO Initiative on Alzheimer's
Attending G8 Global CEO Initiative on Alzheimer's.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 0996V IXICO plc 10 December 2013 \n \n\nIXICO announces that CEO Derek Hill will be attending the G8 Global CEO Initiative on\nAlzheimer's Disease\n \n10 December, 2013 - IXCO plc (\"IXICO\" or the \"Company\"), the brain health company, announces that Derek Hill, IXICO's CEO, will attend the G8 Global CEO Initiative on Alzheimer's disease on 12 December, 2013. The CEO Initiative will work with governments, NGOs and other critical stakeholders in the technology, payer, provider and finance industries to achieve the shared goals of preventing and effectively treating Alzheimer's disease by 2025 and enhancing the quality of life of those with the disease and those who care for them.\n \nSpecifically, the G8 Global CEO Initiative on Alzheimer's disease aims to:\n \n· Spur innovation and facilitate opportunities to improve the care of those affected by Alzheimer's;\n· Reduce the time, cost and risk of drug development to improve the productivity of R&D investments;\n· Accelerate a means of prevention and treatment of Alzheimer's, including improving the ability to identify and diagnose the disease;\n· Spur new models for care, care preparation and care delivery, and\n· Re-shape the environment in which society addresses Alzheimer's patients and caregivers.\n \nProfessor Hill is a member of the dementia research champion group, formed in March 2012 by Prime Minister David Cameron to oversee the implementation of the commitments on dementia research in the Dementia Challenge. The group includes some of the country's leading dementia scientists and its work builds on the previous work of the Ministerial Advisory Group on Dementia Research (MAGDR).\n \nFor more information visit: http://www.ceoalzheimersinitiative.org\n \nNotes to editors:\n \nIXICO\n \nIXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase...